Chen Hou1†
Pengyi Li
Chuan Wang- 1School of Basic Medicine, Hengyang Medical College, Institute of Pathogenic Biology, University of South China, Hengyang, China
- 2Department of Clinical Laboratory, Affiliated Hengyang Hospital of Southern Medical University, Hengyang Central Hospital, Hengyang, China
Chlamydia is an obligate intracellular bacterium where most species are pathogenic and infectious, causing various infectious diseases and complications in humans and animals. Antibiotics are often recommended for the clinical treatment of chlamydial infections. However, extensive research has shown that antibiotics may not be sufficient to eliminate or inhibit infection entirely and have some potential risks, including antibiotic resistance. The impact of chlamydial infection and antibiotic misuse should not be underestimated in public health. This study explores the possibility of new therapeutic techniques, including a review of recent studies on preventing and suppressing chlamydial infection by non-antibiotic compounds.
Introduction
Chlamydia and the epidemiology of chlamydial infection
Chlamydia is an obligate intracellular, multi-host, and gram-negative pathogen with a unique developmental cycle (Elwell et al., 2016; Zhong, 2017). It has two main, common, morphologically distinct forms: the infectious elementary body (EB) and the reproductive reticulate body (RB) (Cossé et al., 2018). Elementary bodies can transition into intermediate bodies (IBs) and later differentiate into RBs in an inclusion process (Núñez-Otero et al., 2021). It is worth noting that if exposed to stressful conditions, like penicillin, IFN-γ, or lack of essential nutrients in vitro, Chlamydia may enter a stable state containing enlarged but non-infectious aberrant RBs (ABs) (Hammerschlag, 2002; Panzetta et al., 2018). Persistence represents the attempt of the host to control Chlamydia. Meanwhile, Chlamydia has developed corresponding mechanisms for escaping the host immune response, especially by constructing an immune-evasive persistent state. The persistent state is helpful for Chlamydia since it is a widespread pathogen (Gracey and Inman, 2011).
Most chlamydial species are pathogenic and infectious, particularly Chlamydia trachomatis, Chlamydia pneumonia, and Chlamydia psittaci, which are human pathogens. In 2020, the Centers for Disease Control and Prevention (CDC) reported that the number of C. trachomatis infections had reached 1,579,885 cases in the United States (Sexually Transmitted Disease Surveillance, 2020). This pathogen is one of the major causes of sexually transmitted infections (STIs) in the United States. It can cause anogenital tract infectious diseases and multiple sequelae, including pelvic inflammatory disease, ectopic pregnancy, infertility, and epididymitis. It can also accelerate the acquisition and transmission of the human immunodeficiency virus (HIV) in both sexes (Cornelisse et al., 2017; Panzetta et al., 2018; National Academies of Sciences, Engineering, and Medicine et al., 2021). As the most common infections among humans, STIs have caused significant morbidity and mortality in the United States and worldwide. C. trachomatis infections can also lead to conjunctivitis, trachoma, and subacute and afebrile pneumonia. Conversely, C. pneumoniae is the primary cause of human respiratory diseases, including pneumonia and bronchitis. Approximately 10% of community-acquired pneumonia and 5% of bronchitis result from C. pneumoniae infection (Roulis et al., 2013). As knowledge of C. pneumoniae increases, it appears to be associated with certain chronic diseases, including asthma, chronic obstructive pulmonary disease, atherosclerotic cardiovascular disease, and lung cancer (Porritt and Crother, 2016; Crother et al., 2019; Khoshbayan et al., 2021; Premachandra and Jayaweera, 2022). However, it is crucial to determine the exact relationship between C. pneumoniae infection and related diseases through further clinical studies. Psittacosis caused by C. psittaci is a zoonotic disease with various clinical symptoms, such as fever, headache, muscle aches, malaise, chills, pneumonia, non-productive coughing, and respiratory distress (Beeckman and Vanrompay, 2009; Shaw et al., 2019; Li N. et al., 2021). A previous study found significant differences in the epidemiology of psittacosis by gender by descriptively analyzing psittacosis cases reported in Japan from 2007 to 2016. Yet, the reasons leading to gender differences are uncertain and remain to be solved (Kozuki et al., 2020). Overall, Chlamydia can infect various areas, including the ocular mucosa, respiratory tract, and anogenital tract, causing a variety of infectious diseases and complications in humans and animals. In terms of public health, the chlamydial infection has long been an adversary not to be underestimated. Thus, safe and effective treatment should be provided for patients with chlamydial infections.
Traditional therapy: Antibiotics
Antibiotics are often recommended for clinical chlamydial infections (Schachter and Caldwell, 1980; Clarke, 2011). Notably, there can be differences in the clinical symptoms of infection, sensitivity to antibiotics, and caution against various antibiotics among different infection sites. Thus, it is necessary to choose a suitable treatment based on the chlamydial infection site (Doernberg et al., 2020; Man et al., 2021). According to the STI treatment guidelines presented by the CDC in 2021 (CDC, 2022), doxycycline, azithromycin, levofloxacin, amoxicillin, erythromycin base, or ethylsuccinate are used to treat C. trachomatis infection. However, particular recommendations and different regimens should be followed for C. trachomatis infections in pregnant women, neonates, infants, children, adolescents, and adults.
Although antibiotics have been considered the standard treatment for chlamydial infections, some disadvantages of the treatment make it somewhat limited. Misuse of antibiotics is likely to disrupt the gut microbial community and increase the risk of the emergence of antibiotic-resistant chlamydial species or bacteria (Fröhlich et al., 2016; Angelucci et al., 2019; Benamri et al., 2021). For example, treating C. trachomatis infections with azithromycin can lead to resistance in Streptococcus pneumoniae and Mycoplasma genitalium (Jensen et al., 2008; O'Brien et al., 2019; Núñez-Otero et al., 2021). Many tetracyclines, i.e., antibiotic growth promoters, are supplied with livestock feed and may be the main reason for inducing stable tetracycline resistance in Chlamydia suis (Roberts, 1996; Chopra and Roberts, 2001; Dugan et al., 2004). Presently, human chlamydial strains do not show tetracycline resistance. Although antimicrobial resistance in Chlamydia is currently sporadic in the clinical setting, it still poses a public health threat (Dugan et al., 2004). Particularly, tetracyclines (i.e., doxycycline) are used as the first-line treatment for C. trachomatis at all infection sites (except Trachoma) and increase this misuse (Lau et al., 2021; Fairley et al., 2022). It is worth noting that various gene mutations in Chlamydial species are associated with antibiotic resistance. For example, C. trachomatis and C. psittai may develop resistance to macrolides through mutations in the 23S rRNA gene.
Furthermore, gene sequencing of the susceptible and resistant C. trachomatis strains revealed mutations in the A2057G, A2059G, and T2611C peptidyl transferase regions of the 23S rRNA gene related to antibiotic resistance (Benamri et al., 2021). In addition, antibiotic misuse is closely associated with treatment failure of chlamydial infection (Kardas et al., 2005). Research has shown that heterotypic resistance and single-dose therapy with a bacteriostatic antibiotic may be a biologically rational explanation for the failure of azithromycin treatment of C. trachomatis (Horner, 2012). In vitro evidence showed that if Chlamydia is exposed to stress conditions caused by penicillin (belonging to β-lactam antibiotics) and IFN-γ during replication, it may enter a particular state called “chlamydial persistence” (Hocking et al., 2015; Panzetta et al., 2018). Stress conditions mainly include impaired ATP production, oxidative stress, feedback regulation of cellular core processes, induction of the stringent response with the alarmone guanosine tetra- and pentaphosphate or the RpoS-mediated general stress response, and the added release of the toxin component (Eisenreich et al., 2022). Persistent chlamydial infection, a health hazard that should not be ignored, usually has a long incubation period and shows mild or even asymptomatic clinical symptoms. Also, most C. trachomatis infections, especially genital, rectal, and oral infections, are asymptomatic (Bogdanov et al., 2014; Vodstrcil et al., 2015; Adamson and Klausner, 2018; Hiransuthikul et al., 2019; Durukan et al., 2020). Therefore, it is essential to screen for STIs to prevent and control C. trachomatis infections and maintain public health safety. Currently, the most common approach for detecting C. trachomatis is nucleic acid amplification tests (NAATs), which have a high degree of sensitivity and specificity (Gaydos et al., 2004; Durukan et al., 2020).
Non-antibiotic approaches
Chlamydial infection and antibiotic resistance are important threats to public health safety. It is crucial to optimize the use of antibiotics and develop new drugs or treatments that selectively target Chlamydia to limit the likelihood of the emergence of resistant strains. Several researchers have recently suggested that certain non-antibiotic substances can inhibit chlamydial infection through various mechanisms and may be promising candidates for anti-Chlamydial drugs (Table 1).
Table 1. Past studies exploring the anti-chlamydial properties of non-antibiotic approaches.
Synthetic drugs
Antibiotic resistance is a major public health concern; hence, compounds that are selectively effective against Chlamydia are of great interest for reducing pressure on antibiotic resistance in commensal and pathogenic bacteria. Here, we list several synthetic compounds with potential anti-Chlamydial activity and discuss their corresponding mechanisms.
Wolf et al. demonstrated that a small molecule of Yersinia T3SS inhibitor, designated compound 1 (C1), inhibits the development of C. trachomatis (Wolf et al., 2006). The expression of T3SS presumably helps Chlamydia establish and maintain the intracellular infection status by secreting anti-host proteins. Thus, inhibiting the T3SS compound is promising for treating chlamydial infection (Wolf et al., 2006). This anti-Chlamydial mechanism has also been confirmed in subsequent studies. For example, Muschiol et al. demonstrated that INP0400 (a small-molecule inhibitor of T3SS) also played a distinctive role in different stages of C. trachomatis infection (Muschiol et al., 2006). At a concentration of 10 μM, INP0400 can inhibit RB replication and reduce the number of inclusions in the early stage (Muschiol et al., 2006). At the later stage, INP0400 can cause the separation of RBs from the inclusion membrane and inhibit the transformation of RB into EB, leading to a significant decrease in infection (Muschiol et al., 2006). Another study found that inhibitors of bacterial type III secretion (T3S), ME0177 and ME0192, may be considered for systemic and topical treatment of chlamydial infection by individual pharmacokinetic analysis (Ur-Rehman et al., 2012). Importantly, ME0192 can inhibit C. trachomatis genital infection in mice but not the normal vaginal flora (Ur-Rehman et al., 2012). Results from this study suggest that vaginal microbicides may be considered candidates against local chlamydial infection. In particular, the nonoxynol-9 (N-9) formulated foam was demonstrated to prevent simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection in rhesus macaques (Miller et al., 1992; Weber et al., 2001). However, some clinical trials suggested that N-9 does not protect against certain STI-induced microbes, including Neisseria gonorrhoeae, C. trachomatis, Trichomonas vaginalis, and HIV (Wilkinson et al., 2002).
Moreover, gonorrhea and the HIV infection rate appeared to be higher in women using the N-9 gel (Richardson et al., 2001; Van Damme et al., 2002). Nonoxynol-9 was not developed into a vaginal microbicide mainly due to its low efficiency in killing microbes and causing vaginal epithelium damage that promotes microbes' entry into women's bodies. Thus, the integrity of the female reproductive tract is considered to be an important evaluation criterion for vaginal microbicides (Tanphaichitr et al., 2016). Detection of vaginal toxicity, such as irritation, ulcerations, and histological inflammation of the vaginal microbicides, also plays a vital role.
Additionally, Osaka and Hefty (2014) found that low concentrations of lipopolysaccharide-binding alkyl polyamine DS-96 can block EB infection during the attachment phase and inhibit the growth of Chlamydia. Synthetic polymers, like sulfonated synthetic polymers called poly (sodium 4-styrene sulfonate/acid; PSS) and polyanetholsulfonic acid sodium salt (SPS), can suppress the formation of chlamydial inclusion in a concentration-dependent manner (Gallegos et al., 2018). Several small-molecule inhibitors with anti-Chlamydial activity have been reported. For instance, adding the inhibitor JO146, which targets the HtrA serine protease, during the replication phase of C. trachomatis can destroy the typical morphology of RB, decrease the inclusion size, and finally inhibit the formation of viable EB (Gloeckl et al., 2013). Similarly, the small-molecule inhibitor H89 decreases the production of chlamydial progeny by reducing RB replication and interfering with RB to EB conversion (Muñoz et al., 2021). In addition, a molecule inhibitor, MK2206, can alter host lipid synthesis and cholesterol transfer to reduce the conversion of RB to EB (Muñoz et al., 2022). Based on these studies, small-molecule inhibitors interfere with the development and infection of Chlamydia by reducing the production of EB, altering inclusion size, and disrupting RB to EB conversion. Inhibitors targeting the developmental cycle of Chlamydia may be a new anti-Chlamydial therapeutic strategy.
Natural compounds and anti-infective action
Polyphenols
Polyphenols are bioactive molecules widely distributed in fruits, vegetables, grains, and beverages. Some have the potential for an antibacterial activity where antibiotic synergy inhibits bacterial virulence (Vuorelaa et al., 2004; Cushnie and Lamb, 2011; Fiorentini et al., 2015). Thus, studies have tried to use polyphenols in anti-Chlamydia experiments and found that certain compounds have specific anti-Chlamydia effectiveness (Table 1). Polyphenols have multiple modes of action against Chlamydia, but the exact mechanism of action needs further study. Alvesalo et al. showed that polyphenols' structure might influence the anti-Chlamydial effect (Alvesalo et al., 2006). Natural flavonoids and synthetic structural analogs have been shown to inhibit C. pneumoniae in in vitro experiments, and flavonoids without sugar moieties have higher anti-C. pneumoniae activity than those with other structures (Alvesalo et al., 2006).
Catechins, a type of flavan-3-ol flavonoid, are ubiquitous constituents of vascular plants and have broad-spectrum antimicrobial properties (Lambert et al., 2007; Sajilata et al., 2008). It can damage the plasma membrane by disrupting the lipid bilayer's permeability (Lambert et al., 2007). This direct antibacterial mechanism supports the broad-spectrum antibacterial properties observed in other studies (Lambert et al., 2007; Sajilata et al., 2008; Li et al., 2019). Catechins can control influenza viruses, coronaviruses, and oral microbial infectious diseases (Lambert et al., 2007; Furushima et al., 2018; Reygaert, 2018; Li et al., 2019; Yang et al., 2021). Yamazaki et al. investigated the anti-Chlamydial effects in vitro of five catechin-rich tea polyphenols, including catechin, epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate (Yamazaki et al., 2003, 2005). All the tea polyphenols tested had inhibitory effects on chlamydial proliferation. The C. pneumoniae strains, AC-43 and AR-39, were inhibited entirely with the tea polyphenols at concentrations of 1.6 and 0.8 mg/mL, respectively. For serotypes D and L2, C. trachomatis was completely suppressed with the tea polyphenols at concentrations of 1.6 and 0.4 mg/mL, respectively.
Moreover, epigallocatechin gallate is considered to be the main component of the observed antibacterial effect (Yamazaki et al., 2003, 2005). Studies have shown that each tea polyphenol can be applied topically but not orally to treat systemic infections. Because the concentration of tea polyphenols required for complete inhibition of C. trachomatis is high compared to antibiotics, the toxicity will increase with an increased dose; thus, tea polyphenols are not currently suitable for treating systemic infections (Yamazaki et al., 2003, 2005). More research is needed to determine if targeting the structure of the tea polyphenol can lead to the creation of more potent systemic drugs.
Luteolin is a flavone found in vegetables, fruits, and medicinal herbs (Aziz et al., 2018). It can inhibit phosphorylation, a proinflammatory cytokine, and chemokine production in vitro or in animal models, and it has antioxidant, antibacterial, and anti-inflammatory properties (Kotanidou et al., 2002; Imran et al., 2019). Tormakangas et al. have evaluated the effects of acute C. pneumoniae infection treatment with the flavonoids, quercetin, luteolin, alkyl gallate, and octyl gallate in a mouse model and found that luteolin was able to suppress C. pneumoniae inflammation in lung tissue. Their study suggests that luteolin attenuates the inflammatory response induced by chlamydial infection through a cascade of NF-κB-mediated effects. Luteolin may also interfere with the mitochondrial pathway to induce apoptosis and eliminate the anti-apoptotic effect of Chlamydia (Törmäkangas et al., 2005). However, it is essential to note that luteolin treatment can reduce the production of C. pneumoniae-specific antibodies, possibly because luteolin directly reduces the natural inflammatory process and decreases the immune response (Törmäkangas et al., 2005).
Baicalin is a flavone derived from the raw, dry root of Scutellaria baicalensis, which has anti-inflammatory, anti-tumor, and antiviral activity (Jiang et al., 2020). Baicalin is an effective anti-Chlamydial agent and can potentially treat anti-Chlamydial infectious diseases both in cells and in animal experiments (Hao et al., 2010). A previous study has shown that baicalin can successfully block the C. trachomatis infection of HEP-2 cells (Hao et al., 2009). Ongoing research demonstrates that baicalin might affect the expression of chlamydial protease-like activity factor (CPAF) in HEP-2 cells with C. trachomatis infection. Baicalin can target and down-regulate CPAF production so that the immune system can detect chlamydial infection more effectively (Fan et al., 2002; Hao et al., 2009). Furthermore, studies have demonstrated that CPAF degrades host transcription factors, including RFX5, which is necessary for Chlamydia to evade host immune recognition defense mechanisms (Hao et al., 2010). Hao et al. have suggested that baicalin can block C. trachomatis infection by inhibiting the toll-like receptors 2 and 4 (TLR 2/4) and nuclear factor-κB (NF-κB) signaling pathways in genital tract cervical tissue infected with C. trachomatis in mice (Hao et al., 2012).
Lipids
Since some lipids have broad-spectrum antibacterial effects, especially targeting gram-negative bacteria (Lee et al., 2013), it is theorized that lipids may be used against Chlamydia (gram-negative bacterium). In fact, experiments have shown that parts of lipids have anti-chlamydia activity and can destroy the membrane, which may be the primary mechanism (Yoon et al., 2015, 2018; Casillas-Vargas et al., 2021). Bergsson et al. have proved that monocaprine, lauric acid, and decanoic acid have the strongest activity against C. trachomatis infection among 12 lipidic compounds (Bergsson et al., 1998). Synthetic lipids have also been shown to have potential as topical fungicides (Mansouri et al., 2021). Lampe et al. studied five active synthetic lipids developed from human milk (Lampe et al., 1998). When applied at 7.5 mM for 120 min, 2-O-octyl-sn-glycerol completely inhibited the growth of C. trachomatis compared with the other four lipids (Lampe et al., 1998). Considering that C. trachomatis is a sexually transmitted disease, the study also evaluated the anti-Chlamydial effect of 2-O-octyl-sn-glycerol under conditions similar to the human vagina (10% of human blood, pH 4.0–8.0). After exposing EBs to 50 mM 1-O-hexyl-sn-glycerol for 90 min, EBs appeared to have a hollow shell, ruptured cell membranes, and cytoplasmic contents leaking from the cell (Lampe et al., 1998). These results support the direct damage and/or destruction of the chlamydial lipid membrane and the potential anti-Chlamydial activity of 2-O-octyl-sn-glycerol (Lampe et al., 1998). Furthermore, Skinner et al. explored the development of topical microbicides using the synthetic lipid 3-O-octyl-sn-glycerol [3-OG] and the engineered antimicrobial peptide, WLBU2, as active compounds (Skinner et al., 2010). The authors found that both WLBU2 and 3-OG were effective against C. trachomatis in vitro, and their synergistic inhibitory activities were considerably enhanced (Skinner et al., 2010). Existing studies have demonstrated that lipids have anti-Chlamydial properties mainly related to destroying the pathogen's cell membranes. Still, the exact mechanisms and the selective effect against chlamydia must be explored.
Peptides
Some peptides consist of short amino acid chains that are common antibacterial protein compounds (Yasin et al., 2004). Lazarev et al. explored the use of the antimicrobial peptide melittin in treating chlamydia infections, the main active ingredient in bee venom, in the mid-1990s (Lazarev et al., 2002, 2005, 2007). C. trachomatis was inhibited in vitro by introducing and activating a recombinant plasmid vector expressing the melittin gene. Melittin not only has a direct bactericidal effect on cells (Lazarev et al., 2002) but can also restrict the adhesion of Chlamydia to cells by reducing the transmembrane potential of cells (Lazarev et al., 2005). Cathelicidin peptides, composed of amino acids (usually fewer than 50 amino acids) and cationic, are the building blocks of immune molecules with a wide range of antimicrobial or anti-Chlamydial activity (Francesco et al., 2013; He et al., 2018; Rowe-Magnus et al., 2019). Previous literature reported that SMAP-29 was the most potent antimicrobial peptide against various Chlamydia species compared with the five other antimicrobial peptides. Additionally, BMAP-27, BMAP-28, Bac7(1–35), and PG-1 have also been shown to reduce C. trachomatis and C. pneumoniae inclusion at a concentration of 10 μg/mL (Francesco et al., 2013). A follow-up study has shown that most swine Chlamydia isolates were sensitive to the same type of antimicrobial peptides, especially BMAP-29 (Donati et al., 2007).
Cecropins are a group of cationic peptides with strong antibacterial activity targeting gram-negative and gram-positive bacteria (Brady et al., 2019). Ballweber et al. found that the antimicrobial peptides D2A21 and D4E1 can maintain anti-Chlamydial activity at a proper concentration in human blood (Ballweber et al., 2002). However, pH values above and below seven reduced D2A21 activity, while the activity of the 2% D2A21 gel formulation remained unchanged at different pH values in their experiment (Ballweber et al., 2002). Whether these gel excipients can make D2A21 peptides exert their inherent activity more fully must be further explored. Interestingly, ultrastructural observations showed that exposure of C. trachomatis EBs to peptide D2A21 could lead to membrane dissolution or destruction, but the mechanism is unclear (Ballweber et al., 2002).
Transferrin, a multifunctional protein found in many biological secretions such as milk, tears, and saliva, has anti-inflammatory and antibacterial properties (Wang et al., 2019). Lactoferrin (LF), ovotransferrin (ovoTF), and serum transferrin are the most important members of the transferrin family of iron-binding glycoproteins (Beeckman et al., 2007). Lactoferrin and ovoTF can potentially reduce chlamydial infection in vivo and in vitro (Beeckman et al., 2007; Wang et al., 2019). Likewise, three transferrins have anti-C. psittaci activity, including ovoTF, human lactoferrin (hLF), bovine lactoferrin (bLF), and ovoTF, can stop C. psittaci from attaching to and entering the cell (Beeckman et al., 2007). In a follow-up study, turkeys were sprayed with ovoTF to prevent respiratory disease caused by C. psittaci (Van Droogenbroeck et al., 2008, 2011). The studies found that ovoTF used in farms can (Zhong, 2017) reduce airborne transmission of C. psittaci, (Elwell et al., 2016) reduce the severity of infection, (Cossé et al., 2018) prevent respiratory diseases during the first half of the incubation period, and (Núñez-Otero et al., 2021) produce a synergistic effect with antibiotics. Evidently, the anti-Chlamydial effect of transferrin has been proven not only in C. psittaci but also in other Chlamydia species. Bovine LF (bLF) can inhibit intravaginal C. trachomatis infection and reduce the number of inclusions and the overall replication of C. suis in McCoy cells with C. suis-spiked semen samples (Sessa et al., 2017; Puysseleyr et al., 2021). Taken together, these studies highlight transferrin's potential diversity in antibacterial efficacy and mechanisms. Other peptides, like spider venom peptides and WLBU2, also have anti-Chlamydial effects (Skinner et al., 2010; Lazarev et al., 2011). Although the exact mechanisms by which these peptides confer antibacterial activity have not been clarified, studies suggest that these peptides have tremendous therapeutic potential against chlamydial infection (Yasin et al., 2004; Mwangi et al., 2019).
Cytokines
During chlamydial infection, large amounts of cytokines are secreted by host cells that regulate host immune and inflammatory responses. It should be noted that proper responses are beneficial to remove Chlamydia, inhibit the infection, and reduce the pathological damage. Conversely, inappropriate responses caused by the excessive release of some cytokines can aggravate the infection. Manipulating these key cytokines may be a new strategy worth investigating for treating chlamydial infection.
Although numerous studies have shown that IFN-γ has an anti-Chlamydial function (Leonhardt et al., 2007; Ohman et al., 2011; Virok et al., 2019; Darville, 2021), no IFN-γ drugs target chlamydial infection. Chlamydia and Mycobacterium tuberculosis (Mtb) are pathogenic intracellular pathogens that cause a Th1-type immune response, and IFN-γ plays a significant role in resistance to Chlamydia and Mtb infections (Desvignes et al., 2012). Thus, the use of IFN-γ treating Mtb infections (Condos et al., 1997; Park et al., 2007; Beeckman and Vanrompay, 2009; Gao et al., 2011) may guide the development of anti-Chlamydial drugs. A previous study (Condos et al., 1997) showed that treatment with IFN-γ via aerosol administration helped reduce the bacterial burden in the lungs and even diminished cavitary lesions in a proportion of pulmonary tuberculosis patients. It is worth noting that sputum smears were negative during the 4-week intervention but positive 1–5 months after ending treatment. Further studies must determine whether exogenous IFN-γ long-term treatment can target infectious diseases. Also, observing adverse reactions and the tolerability of treatments is necessary for safety evaluation, even if no systemic side effects occur.
The interleukin (IL) family is an effective group of cytokines that helps promote or inhibit chlamydial infection. Studies have shown that macrophages, Jurkat cells, and THP-1 cells infected with C. trachomatis exhibit more IL-10 receptors than uninfected cells (Hakimi et al., 2014). Likewise, the secretion of IL-10 increases in the early stages of C. trachomatis infection in the male reproductive tract (Sanchez et al., 2019). Azenabor and York induced C. trachomatis-infected macrophages to produce IL-10 by increasing intracellular Ca2+ levels (Azenabor and York, 2010). In another study, the IL-10 level of patients with chlamydial infections was higher than that of uninfected individuals (Han et al., 2006). In a study on intranasal infection with C. psittaci, IL-10−/− mice were found to promote activation and assembly of the NLRP3 inflammasome, promoting apoptosis, and leading to chlamydial clearance (Li Q. et al., 2021). Studies on mice with IL-10 deletion have shown that the loss of this cytokine distorts the anti-Chlamydial immune response, altering the dominant Th1 phenotype, and preventing Chlamydia-induced immunopathology (Bua et al., 2019; Sanchez et al., 2019). Bua et al. also found higher IL-10 levels in infertile women (Bua et al., 2019). Therefore, increased IL-10 expression is not only associated with persistent chlamydial infection but may also be associated with complications of chlamydial infection, such as infertility. Although the mechanism of IL-10 action is still not fully understood, it is undeniable that IL-10 may be a new pathway for chlamydial treatment. Relevant KO mice, siRNA/chemical inhibition, or antibody blockade may be used for identifying the exact mechanism of IL-10 in chlamydial infection. Furthermore, attempting to use the corresponding antibody or inhibitor of IL-10 to control chlamydial infection may be beneficial (Xiang et al., 2021).
Cytokines play a critical role in the fight against tumor cells and pathogens. However, many barriers, such as toxicity-related inherent characteristics, including short half-lives in circulation, inherent pleiotropic functions, and off-target effects, have previously blocked the development of cytokines as immunotherapy drugs (Zheng et al., 2022). With the further study of cytokine immunobiology, immune cytokine drugs are being rapidly developed with new protein engineering and synthetic design technologies, and some have entered clinical trials. For instance, structural engineering can overcome some limitations in the type-I IFN family, including adverse side effects and limited efficacy, and help this family have a broader application prospect in antiviral and antiproliferative clinical practice (Jaitin et al., 2006; Brideau-Andersen et al., 2007; Thomas et al., 2011; Levin et al., 2014). Additionally, studies suggest that selective and accurate modifications of cytokines are useful to enhance their target, efficiency, and long-term efficacy. Moreover, reducing their bioactivity or biological function may be considered a novel way to lessen the toxic reaction (Zheng et al., 2022). In brief, many theories and empirical evidence show that cytokines have therapeutic potential against chlamydial infection but still require future work.
Vaccines
It is widely known that successful vaccination campaigns have effectively prevented life-threatening diseases such as influenza, tetanus, smallpox, and polio (Vashishtha and Kamath, 2016; Pandolfi et al., 2018; Pollard and Bijker, 2021). Without exception, a chlamydia vaccine is also under development and has achieved great expectations thus far (Zhong et al., 2019; Brunham, 2022). Vaccines effectively prevent infectious diseases and play an important role in treating cancer and other diseases (Polaris Observatory Collaborators, 2018; Calabrese, 2021; Chaudhary et al., 2021). For example, a previous study showed that a multivalent vaccine could protect against C. trachomatis infection in vaccinated mice, reduce the C. trachomatis load in the vagina, and prevent pathological changes in the upper genital tract (Olsen et al., 2015). Unvaccinated mice had substantial oviduct pathology, such as pronounced lymphocyte infiltration in the mesosalpinx and ovarian bursa after C. trachomatis infection, compared to the Hirep1-vaccinated mice with no pathological changes. Chlamydial vaccines can suppress infection or slow disease progression by preventing early chlamydial infection from aggravating (Stary et al., 2015; Paes et al., 2016). In addition, vaccines can induce a strong mucosal immune response to suppress C. trachomatis genital infection and reduce long-term sequelae (Ganda et al., 2017). In general, receiving a preventive chlamydial vaccine can induce effective immune responses to prevent and control chlamydial infection in uninfected individuals, but it cannot control existing infections or lesions, and it is not suitable for treating patients. Thus, developing therapeutic vaccines that can contribute to removing pathogens and abnormal cells profoundly influences the treatment of chlamydial infection. Although no therapeutic vaccine has been reported for Chlamydia, existing therapeutic vaccine research on cancer, rheumatic disease, and some infectious diseases, including AIDS and chronic hepatitis B virus, provides a great deal of theoretical evidence and practical experience for a Chlamydia vaccine (Burke, 1993; Bertoletti and Le Bert, 2018; Calabrese, 2021).
Several HIV therapeutic vaccines are already being tested in clinical trials. These vaccines function primarily by activating host-specific immune responses and could improve the T-cell subset homeostasis, which is not completely recovered in HIV-treated patients (Leal et al., 2017). Progress has also been made on a therapeutic vaccine for the human papillomavirus (HPV). The therapeutic vaccine for this virus can promote histopathological regression and virus clearance in patients, eliciting an increased frequency of T-cell responses, which are critical for clearing chlamydial infection (Hancock et al., 2018; Garbuglia et al., 2020). HIV, HPV, and C. trachomatis are known to be sexually transmitted diseases and/or pathogens. From this perspective, a chlamydial therapeutic vaccine can apply the design of HIV and HPV therapeutic vaccines, although further research is recommended (Gray et al., 2009; Sandoz and Rockey, 2010; Hafner and Timms, 2018; Abraham et al., 2019). In addition, each vaccine platform has its own strengths. For instance, the DNA vaccine can induce antigen-specific immunity, has satisfactory safety and stability, and can be manufactured rapidly. The literature shows that the DNA vaccine has great potential for developing a therapeutic HPV vaccine (Cheng et al., 2018). In conclusion, the design of a chlamydial therapeutic vaccine has excellent potential advantages and feasibility and is a promising candidate treatment strategy for chlamydial infectious diseases. Notably, efficacy and security should be actively considered when finding an effective vaccine optimization strategy, such as dominant antigens, adjuvant delivery systems, and vaccination methods.
Perspective
Most chlamydial species can lead to infectious diseases and complications in humans and animals; C. trachomatis is one of the major causes of STIs. Developing timely screening and precise diagnosis is key to controlling the spread of chlamydial infectious diseases. Nevertheless, many obstructions in screening, diagnosis, and treatment cause the prevention and control of chlamydial infections to be sub-optimal. Due to their high sensitivity and specificity, NAATs are the preferred screening techniques for gonorrhea and Chlamydia (National Academies of Sciences, Engineering, and Medicine et al., 2021). However, some factors, such as the high cost, specialized personnel, and lengthy analysis, limit NAAT's application in parts of low- and middle-income countries.
However, the rapid growth in paper microfluidic technologies and isothermal amplification of nucleic acids show a new prospect for sensitive nucleic acid detection tests (Magro et al., 2017). Developing cheaper, faster, more convenient, and more precise diagnostic tools is critical to ensuring prompt treatment and reducing health risks and ongoing STI transmission. Effective treatment is beneficial to better cope with the challenge of the continually rising chlamydial infection rate.
Antibiotic therapy is often the primary clinical treatment against chlamydial infection, but antimicrobial resistance should be considered a potential health threat. Many restrictions and difficulties exist in investigating and overcoming the antimicrobial resistance problems related to anti-Chlamydial infection, such as the lack of a standardized in vitro assay, and the uncertain relation between the experiment results in vitro and clinical outcomes after antibiotic therapy (Cushnie and Lamb, 2011). To reduce the risk of antibiotic resistance and avoid disrupting the commensal flora, we still need to find compounds that have a selective effect against Chlamydia. The developmental cycle of Chlamydia is unique and corresponds to its regulation of gene expression. Therefore, targeting the developmental cycle of Chlamydia and the transcription of chlamydial virulence may be promising pathways for developing highly selective anti-Chlamydial drugs (Núñez-Otero et al., 2021; Seleem et al., 2022). Although it is useful to control and remove chlamydial infections with current drug treatments, it cannot treat irreversible lesions. Thus, it is vital to develop more effective prevention strategies and therapeutic drugs based on the pathogenic mechanisms of Chlamydia (Xiang et al., 2021).
The process of discovering new antibacterial compounds for their clinical application is long and arduous; many compounds are still in the preclinical stage. Taken together, it has been proven that some non-antibiotic substances have the developmental potential to inhibit chlamydial infection. At the same time, efficacy and safety assessments always have some limitations. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation is an innovative technique that links PK profiles with the corresponding PD to improve drug development. Collecting and analyzing PK/PD information for designing optimal dosing strategies, evaluating animal models, and planning clinical studies is crucial. Moreover, some studies suggest that in vitro PK/PD models can be used to estimate antibiotic breakpoints, which is important in inhibiting the development of antibiotic resistance. For future regulatory guidance, pharmaceutical companies and sponsors should consider PK/PD as critical topics for drug development (Schmidt et al., 2008; Bhavnani and Rex, 2017).
In conclusion, antibacterial agents must provide good PK/PD support data. Other critical issues of drug development, such as the mechanism of action, specificity, and toxic side effects, should be addressed. Finally, we will only comprehend the control and effectiveness of drugs with ongoing clinical trials.
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
This work was supported by the Natural Science Foundation of Hunan Province (Grant No. 2021JJ40455), the Projects of the Hunan Health Committee (Grant No. 202112071537), the National Innovation and Entrepreneurship Training program for college students (Grant No. 202110555102), the Innovation and Entrepreneurship Training program for college students of the University of South China (Grant Nos. X202010555371 and X202010555372), and Graduate Student Research Innovation Project of Hunan Province (Grant No. CX20221007).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abraham, S., Juel, H. B., Bang, P., Cheeseman, H. M., Dohn, R. B., Cole, T., et al. (2019). Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. Infect. Dis. 19, 1091–1100. doi: 10.1016/S1473-3099(19)30279-8
Adamson, P. C., and Klausner, J. D. (2018). No benefit of chlamydia screening in primary care? Lancet. 392, 1381–1383. doi: 10.1016/S0140-6736(18)32465-6
Alvesalo, J., Vuorela, H., Tammela, P., Leinonen, M., Saikku, P., Vuorela, P., et al. (2006). Inhibitory effect of dietary phenolic compounds on Chlamydia. pneumoniae in cell cultures. Biochem. Pharmacol. 71, 735–741. doi: 10.1016/j.bcp.2005.12.006
Angelucci, F., Cechova, K., Amlerova, J., and Hort, J. (2019). Antibiotics, gut microbiota, and Alzheimer's disease. J. Neuroinflamm. 16, 108. doi: 10.1186/s12974-019-1494-4
Azenabor, A. A., and York, J. (2010). Chlamydia trachomatis evokes a relative anti-inflammatory response in a free Ca2+ dependent manner in human macrophages. Comp. Immunol. Microbiol. Infect. Dis. 33, 513–528. doi: 10.1016/j.cimid.2009.09.002
Aziz, N., Kim, M. Y., and Cho, J. Y. (2018). Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J. Ethnopharmacol. 225, 342–358. doi: 10.1016/j.jep.2018.05.019
Ballweber, L. M., Jaynes, J. E., Stamm, W. E., and Lampe, M. F. (2002). In vitro microbicidal activities of cecropin peptides D2A21 and D4E1 and gel formulations containing 0, 1. to 2% D2A21 against Chlamydia trachomatis. Antimicrob. Agents. Chemother. 46, 34–41. doi: 10.1128/AAC.46.1.34-41.2002
Beeckman, D. S., Van Droogenbroeck, C. M., Cock, D. e., Van Oostveldt, B. J. P., and Vanrompay, D. C. (2007). Effect of ovotransferrin and lactoferrins on. Chlamydophila. psittaci. adhesion and invasion in HD11 chicken macrophages. Vet. Res. 38, 729–39. doi: 10.1051/vetres:2007028
Beeckman, D. S., and Vanrompay, D. C. (2009). Zoonotic Chlamydophila. psittaci infections from a clinical perspective. Clin. Microbiol. Infect. 15, 11–7. doi: 10.1111/j.1469-0691.2008.02669.x
Benamri, I., Azzouzi, M., Sanak, K., Moussa, A., and Radouani, F. (2021). An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics. Ann. Clin. Microbiol. Antimicrob. 20, 59. doi: 10.1186/s12941-021-00465-4
Bergsson, G., Arnfinnsson, J., Karlsson, S. M., Steingrímsson, O., and Thormar, H. (1998). In vitro inactivation of Chlamydia. trachomatis by fatty acids and monoglycerides. Antimicrob. Agents. Chemother. 42, 2290–4. doi: 10.1128/AAC.42.9.2290
Bertoletti, A., and Le Bert, N. (2018). Immunotherapy for Chronic. Hepatitis. B. Virus Infection. Gut. Liver. 12, 497–507. doi: 10.5009/gnl17233
Bhavnani, S. M., and Rex, J. H. (2017). Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogens. Curr. Opin. Pharmacol. 36, viii–xii. doi: 10.1016/j.coph.2017.11.008
Bogdanov, A., Endrész, V., Urbán, S., Lantos, I., Deák, J., Burián, K., et al. (2014). Application of DNA chip scanning technology for automatic detection of Chlamydia. trachomatis. and Chlamydia. pneumoniae inclusions. Antimicrob. Agents. Chemother. 58, 405–413. doi: 10.1128/AAC.01400-13
Brady, D., Grapputo, A., Romoli, O., and Sandrelli, F. (2019). Insect Cecropins, Antimicrobial Peptides with Potential Therapeutic Applications. Int. J. Mol. Sci. 20, 5862. doi: 10.3390/ijms20235862
Brideau-Andersen, A. D., Huang, X., Sun, S. C., Chen, T. T., Stark, D., Sas, I. J., et al. (2007). Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases. Proc. Natl. Acad. Sci. U. S. A. 104, 8269–8274. doi: 10.1073/pnas.0609001104
Brunham, R. C. (2022). Problems With Understanding Chlamydia. trachomatis Immunology. J. Infect. Dis. 225, 2043–2049. doi: 10.1093/infdis/jiab610
Bua, A., Cannas, S., Zanetti, S., and Molicotti, P. (2019). Levels of different cytokines in women and men with asymptomatic genital infection caused by Chlamydia. J. Infect. Dev. Ctries. 13, 847–850. doi: 10.3855/jidc.9810
Burke, D. S. (1993). Vaccine therapy for HIV: a historical review of the treatment of infectious diseases by active specific immunization with microbe-derived antigens. Vaccine. 11, 883–891. doi: 10.1016/0264-410X(93)90374-7
Calabrese, C. (2021). Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy. Med. Clin. North. Am. 105, 213–225. doi: 10.1016/j.mcna.2020.09.008
Casillas-Vargas, G., Ocasio-Malav,é, C., Medina, S., Morales-Guzmán, C., Del Valle, R. G., Carballeira, N. M., et al. (2021). Antibacterial fatty acids: An update of possible mechanisms of action and implications in the development of the next-generation of antibacterial agents. Prog. Lipid. Res. 82, 101093. doi: 10.1016/j.plipres.2021.101093
CDC (2022). Chlamydial Infections–Chlamydial Infection Among Adolescents and Adults. Available online at: https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm (May 11, 2022).
Chaudhary, N., Weissman, D., and Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug. Discov. 20, 817–838. doi: 10.1038/s41573-021-00283-5
Cheng, M. A., Farmer, E., Huang, C., Lin, J., Hung, C. F., Wu, T. C., et al. (2018). Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. Hum. Gene. Ther. 29, 971–996. doi: 10.1089/hum.2017.197
Chopra, I., and Roberts, M. (2001). Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232–260. doi: 10.1128/MMBR.65.2.232-260.2001
Clarke, I. N. (2011). Evolution of Chlamydia. trachomatis. Ann. N. Y. Acad. Sci. 1230, E11–8. doi: 10.1111/j.1749-6632.2011.06194.x
Condos, R., Rom, W. N., and Schluger, N. W. (1997). Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet. 349, 1513–1515. doi: 10.1016/S0140-6736(96)12273-X
Cornelisse, V. J., Sherman, C. J., Hocking, J. S., Williams, H., Zhang, L., Chen, M. Y., et al. (2017). Concordance of chlamydia infections of the rectum and urethra in same-sex male partnerships: a cross-sectional analysis. BMC Infect. Dis. 17, 22. doi: 10.1186/s12879-016-2141-7
Cossé, M. M., Hayward, R. D., and Subtil, A. (2018). One Face of. Chlamydia. trachomatis: The Infectious Elementary Body. Curr. Top. Microbiol. Immunol. 412, 35–58. doi: 10.1007/82_2016_12
Crother, T. R., Porritt, R. A., Dagvadorj, J., Tumurkhuu, G., Slepenkin, A. V., Peterson, E. M., et al. (2019). Autophagy Limits Inflammasome During Chlamydia. pneumoniae. Infection. Front. Immunol. 10, 754. doi: 10.3389/fimmu.2019.00754
Cushnie, T. P., and Lamb, A. J. (2011). Recent advances in understanding the antibacterial properties of flavonoids. Int. J. Antimicrob. Agents. 38, 99–107. doi: 10.1016/j.ijantimicag.2011.02.014
Darville, T. (2021). Pelvic Inflammatory Disease Due to Neisseria. gonorrhoeae and Chlamydia. trachomatis: Immune Evasion Mechanisms and Pathogenic Disease Pathways. J. Infect. Dis. 224, S39–S46. doi: 10.1093/infdis/jiab031
Desvignes, L., Wolf, A. J., and Ernst, J. D. (2012). Dynamic roles of type I and type II IFNs in early infection with Mycobacterium. tuberculosis. J. Immunol. 188, 6205–15. doi: 10.4049/jimmunol.1200255
Doernberg, S. B., Komarow, L., Tran, T. T. T., Sund, Z., Pandori, M. W., Jensen, D., et al. (2020). Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal. Neisseria. gonorrhoeae and Chlamydia. trachomatis Using a Master Protocol. Clin. Infect. Dis. 71, 2314–2322. doi: 10.1093/cid/ciz1105
Donati, M., Francesco, D. i., Gennaro, A., Benincasa, R., Magnino, M., Pignanelli, S. S., et al. (2007). Sensitivity of Chlamydia. suis to cathelicidin peptides. Vet. Microbiol. 123, 269–273. doi: 10.1016/j.vetmic.2007.02.011
Dugan, J., Rockey, D. D., Jones, L., and Andersen, A. A. (2004). Tetracycline resistance in Chlamydia. suis mediated by genomic islands inserted into the chlamydial inv-like gene. Antimicrob. Agents. Chemother. 48, 3989–3995. doi: 10.1128/AAC.48.10.3989-3995.2004
Durukan, D., Read, T. R. H., Bradshaw, C. S., Fairley, C. K., Williamson, D. A., Petra, D. e., et al. (2020). Pooling Pharyngeal, Anorectal, and Urogenital Samples for Screening Asymptomatic Men Who Have Sex with Men for Chlamydia. trachomatis and Neisseria. gonorrhoeae. J. Clin. Microbiol. 58, e01969–19. doi: 10.1128/JCM.01969-19
Eisenreich, W., Rudel, T., Heesemann, J., and Goebel, W. (2022). Link Between Antibiotic Persistence and Antibiotic Resistance in Bacterial Pathogens. Front. Cell. Infect. Microbiol. 12, 900848. doi: 10.3389/fcimb.2022.900848
Elwell, C., Mirrashidi, K., and Engel, J. (2016). Chlamydia cell biology and pathogenesis. Nat. Rev. Microbiol. 14, 385–400. doi: 10.1038/nrmicro.2016.30
Fairley, C. K., Hocking, J. S., and Kong, F. Y. S. (2022). Doxycycline: the universal treatment for anogenital. chlamydia. Lancet. Infect. Dis. 22, 1102–1103. doi: 10.1016/S1473-3099(22)00173-6
Fan, P., Dong, F., Huang, Y., and Zhong, G. (2002). Chlamydia. pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors required for [correction of factors is required for] major histocompatibility complex antigen expression. Infect. Immun. 70, 345–349. doi: 10.1128/IAI.70.3.1664a-1664a.2002
Fiorentini, D., Zambonin, L., Dalla Sega, F. V., and Hrelia, S. (2015). Polyphenols as modulators of aquaporin family in health and disease. Oxid. Med. Cell. Longev. 2015, 196914. doi: 10.1155/2015/196914
Francesco, A. D., Favaroni, A., and Donati, M. (2013). Host defense peptides: general overview and an update on their activity against Chlamydia. spp. Expert. Rev. Anti. Infect. Ther. 1111. doi: 10.1586/14787210.2013.841450
Fröhlich, E. E., Farzi, A., Mayerhofer, R., Reichmann, F., Jačan, A., Wagner, B., et al. (2016). Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication. Brain. Behav. Immun. 56, 140–155. doi: 10.1016/j.bbi.2016.02.020
Furushima, D., Ide, K., and Yamada, H. (2018). Effect of Tea Catechins on Influenza Infection and the Common Cold with a Focus on Epidemiological/Clinical Studies. Molecules. 23, 1795. doi: 10.3390/molecules23071795
Gallegos, K. M., Taylor, C. R., Rabulinski, D. J., Del Toro, R., Girgis, D. E., Jourha, D., et al. (2018). A Synthetic, Small, Sulfated Agent Is a Promising Inhibitor of Chlamydia. spp. Infection. in. vivo. Front. Microbiol. 9, 3269. doi: 10.3389/fmicb.2018.03269
Ganda, I. S., Zhong, Q., Hali, M., Albuquerque, R. L. C., Padilha, F. F., Rocha, d. a. S. R. P., et al. (2017). Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia. trachomatis genital infection. Int. J. Pharm. 527, 79–91. doi: 10.1016/j.ijpharm.2017.05.045
Gao, X. F., Yang, Z. W., and Li, J. (2011). Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Infect. Dis. 15, e594–600. doi: 10.1016/j.ijid.2011.05.002
Garbuglia, A. R., Lapa, D., Sias, C., Capobianchi, M. R., and Del Porto, P. (2020). The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Front. Immunol. 11, 188. doi: 10.3389/fimmu.2020.00188
Gaydos, C. A., Theodore, M., Dalesio, N., Wood, B. J., and Quinn, T. C. (2004). Comparison of three nucleic acid amplification tests for detection of Chlamydia. trachomatis in urine specimens. J. Clin. Microbiol. 42, 3041–5. doi: 10.1128/JCM.42.7.3041-3045.2004
Gloeckl, S., Ong, V. A., Patel, P., Tyndall, J. D., Timms, P., Beagley, K. W., et al. (2013). Identification of a serine protease inhibitor which causes inclusion vacuole reduction and is lethal to Chlamydia. trachomatis. Mol. Microbiol. 89, 676–689. doi: 10.1111/mmi.12306
Gracey, E., and Inman, R. D. (2011). Chlamydia-induced ReA: immune imbalances and persistent pathogens. Nat. Rev. Rheumatol. 8, 55–9. doi: 10.1038/nrrheum.2011.173
Gray, R. T., Beagley, K. W., Timms, P., and Wilson, D. P. (2009). Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia. trachomatis infection. J. Infect. Dis. 199, 1680–1688. doi: 10.1086/598983
Hafner, L. M., and Timms, P. (2018). Development of a Chlamydia. trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects. Expert. Rev. Vaccines. 17, 57–69. doi: 10.1080/14760584.2018.1417044
Hakimi, H., Zare-Bidaki, M., Zainodini, N., Assar, S., and Arababadi, M. K. (2014). Significant roles played by IL-10 in Chlamydia infections. Inflammation. 37, 818–23. doi: 10.1007/s10753-013-9801-1
Hammerschlag, M. R. (2002). The intracellular life of chlamydiae. Sem. Pediatric. Infect. Dis. 13, 239–48. doi: 10.1053/spid.2002.127201
Han, X., Wang, S., Fan, Y., Yang, J., Jiao, L., Qiu, H., et al. (2006). Chlamydia infection induces ICOS ligand-expressing and IL-10-producing dendritic cells that can inhibit airway inflammation and mucus overproduction elicited by allergen challenge in BALB/c mice. J. Immunol. 176, 5232–5239. doi: 10.4049/jimmunol.176.9.5232
Hancock, G., Hellner, K., and Dorrell, L. (2018). Therapeutic HPV vaccines. Best. Pract. Res. Clin. Obstet. Gynaecol. 47, 59–72. doi: 10.1016/j.bpobgyn.2017.09.008
Hao, H., Aixia, Y., Dan, L., Lei, F., Nancai, Y., Wen, S., et al. (2009). Baicalin suppresses expression of Chlamydia protease-like activity factor in Hep-2 cells infected by Chlamydia. trachomatis. Fitoterapia. 80, 448–52. doi: 10.1016/j.fitote.2009.06.004
Hao, H., Aixia, Y., Lei, F., Nancai, Y., and Wen, S. (2010). Effects of baicalin on. Chlamydia. trachomatis infection in vitro. Planta. Med. 76, 76–8. doi: 10.1055/s-0029-1185943
Hao, H., Gufu, H., Lei, F., Dang, L., and Zhongliang, Y. (2012). Baicalin suppresses expression of TLR2/4 and NF-κB in. chlamydia. trachomatis-infected mice. Immunopharmacol. Immunotoxicol. 34, 89–94. doi: 10.3109/08923973.2011.580756
He, M., Zhang, H., Li, Y., Wang, G., Tang, B., Zhao, J., et al. (2018). Cathelicidin-Derived Antimicrobial Peptides Inhibit Zika. Virus Through Direct Inactivation and Interferon Pathway. Front. Immunol. 9, 722. doi: 10.3389/fimmu.2018.00722
Hiransuthikul, A., Janamnuaysook, R., Sungsing, T., Jantarapakde, J., Trachunthong, D., Mills, S., et al. (2019). High burden of chlamydia and gonorrhoea in pharyngeal, rectal and urethral sites among Thai transgender women: implications for anatomical site selection for the screening of STI. Sex. Transm. Infect. 95, 534–539. doi: 10.1136/sextrans-2018-053835
Hocking, J. S., Kong, F. Y., Timms, P., Huston, W. M., and Tabrizi, S. N. (2015). Treatment of rectal chlamydia infection may be more complicated than we originally thought. J. Antimicrob. Chemother. 70, 961–964. doi: 10.1093/jac/dku493
Horner, P. J. (2012). Azithromycin antimicrobial resistance and genital Chlamydia. trachomatis infection: duration of therapy may be the key to improving efficacy. Sex. Transm. Infect. 88, 154–156. doi: 10.1136/sextrans-2011-050385
Imran, M., Rauf, A., Abu-Izneid, T., Nadeem, M., Shariati, M. A., Khan, I. A., et al. (2019). Luteolin, a flavonoid, as an anticancer agent: A review. Biomed. Pharmacother. 112, 108612. doi: 10.1016/j.biopha.2019.108612
Jaitin, D. A., Roisman, L. C., Jaks, E., Gavutis, M., Piehler, J., Van der Heyden, J., et al. (2006). Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol. Cell. Biol. 26, 1888–1897. doi: 10.1128/MCB.26.5.1888-1897.2006
Jensen, J. S., Bradshaw, C. S., Tabrizi, S. N., Fairley, C. K., and Hamasuna, R. (2008). Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin. Infect. Dis. 47, 1546–1553. doi: 10.1086/593188
Jiang, M., Li, Z., and Zhu, G. (2020). Immunological regulatory effect of flavonoid baicalin on innate immune toll-like receptors. Pharmacol. Res. 158, 104890. doi: 10.1016/j.phrs.2020.104890
Kardas, P., Devine, S., Golembesky, A., and Roberts, C. (2005). A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int. J. Antimicrob. Agents. 26, 106–13. doi: 10.1016/j.ijantimicag.2005.04.017
Khoshbayan, A., Taheri, F., Moghadam, M. T., Chegini, Z., and Shariati, A. (2021). The association of. Chlamydia. pneumoniae infection with atherosclerosis: Review and update of in vitro and animal studies. Microb. Pathog. 154, 104803. doi: 10.1016/j.micpath.2021.104803
Kotanidou, A., Xagorari, A., Bagli, E., Kitsanta, P., Fotsis, T., Papapetropoulos, A., et al. (2002). Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am. J. Respir. Crit. Care. Med. 165, 818–23. doi: 10.1164/ajrccm.165.6.2101049
Kozuki, E., Arima, Y., Matsui, T., Sanada, Y., Ando, S., Sunagawa, T., et al. (2020). Human psittacosis in Japan: notification trends and differences in infection source and age distribution by gender, 2007 to 2016. Ann. Epidemiol. 44, 60–63. doi: 10.1016/j.annepidem.2020.03.001
Lambert, J. D., Sang, S., and Yang, C. S. (2007). Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol. Pharm. 4, 819–825. doi: 10.1021/mp700075m
Lampe, M. F., Ballweber, L. M., Isaacs, C. E., Patton, D. L., and Stamm, W. E. (1998). Killing of Chlamydia. trachomatis by novel antimicrobial lipids adapted from compounds in human breast milk. Antimicrob. Agents. Chemother. 42, 1239–44. doi: 10.1128/AAC.42.5.1239
Lau, A., Kong, F. Y. S., Fairley, C. K., Templeton, D. J., Amin, J., Phillips, S., et al. (2021). Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia. trachomatis. N. Engl. J. Med. 384, 2418–2427. doi: 10.1056/NEJMoa2031631
Lazarev, V. N., Parfenova, T. M., Gularyan, S. K., Misyurina, O. Y., Akopian, T. A., Govorun, V. M., et al. (2002). Induced expression of melittin, an antimicrobial peptide, inhibits infection by Chlamydia. trachomatis and Mycoplasma. hominis in a HeLa cell line. Int. J. Antimicrob. Agents. 19, 133–7. doi: 10.1016/S0924-8579(01)00479-4
Lazarev, V. N., Polina, N. F., Shkarupeta, M. M., Kostrjukova, E. S., Vassilevski, A. A., Kozlov, S. A., et al. (2011). Spider venom peptides for gene therapy of Chlamydia infection. Antimicrob. Agents. Chemother. 55, 5367–5369. doi: 10.1128/AAC.00449-11
Lazarev, V. N., Shkarupeta, M. M., Kostryukova, E. S., Levitskii, S. A., Titova, G. A., Akopian, T. A., et al. (2007). Recombinant plasmid constructs expressing gene for antimicrobial peptide melittin for the therapy of Mycoplasma and chlamydia infections. Bull. Exp. Biol. Med. 144, 452–6. doi: 10.1007/s10517-007-0350-1
Lazarev, V. N., Shkarupeta, M. M., Titova, G. A., Kostrjukova, E. S., Akopian, T. A., Govorun, V. M., et al. (2005). Effect of induced expression of an antimicrobial peptide melittin on Chlamydia. trachomatis and Mycoplasma. hominis infections in vivo. Biochem. Biophys. Res. Commun. 338, 946–950. doi: 10.1016/j.bbrc.2005.10.028
Leal, L., Lucero, C., Gatell, J. M., Gallart, T., Plana, M., García, F., et al. (2017). New challenges in therapeutic vaccines against HIV infection. Expert. Rev. Vaccines. 16, 587–600. doi: 10.1080/14760584.2017.1322513
Lee, C. R., Lee, J. H., Jeong, B. C., and Lee, S. H. (2013). Lipid a biosynthesis of multidrug-resistant pathogens - a novel drug target. Curr. Pharm. Des. 19, 6534–50. doi: 10.2174/13816128113199990494
Leonhardt, R. M., Lee, S. J., Kavathas, P. B., and Cresswell, P. (2007). Severe tryptophan starvation blocks onset of conventional persistence and reduces reactivation of Chlamydia. trachomatis. Infect. Immun. 75, 5105–5117. doi: 10.1128/IAI.00668-07
Levin, D., Schneider, W. M., Hoffmann, H. H., Yarden, G., Busetto, A. G., Manor, O., et al. (2014). Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal. 7, ra50. doi: 10.1126/scisignal.2004998
Li, N., Li, S., Tan, W., Wang, H., Xu, H., Wang, D., et al. (2021). Metagenomic next-generation sequencing in the family outbreak of psittacosis: the first reported family outbreak of psittacosis in China under COVID-19. Emerg. Microbes. Infect. 10, 1418–1428. doi: 10.1080/22221751.2021.1948358
Li, Q., Li, X., Quan, H., Wang, Y., Qu, G., Shen, Z., et al. (2021). IL-10(-/-) Enhances DCs Immunity Against Chlamydia. psittaci Infection via OX40L/NLRP3 and IDO/Treg Pathways. Front. Immunol. 12, 645653. doi: 10.3389/fimmu.2021.645653
Li, Y., Jiang, X., Hao, J., Zhang, Y., and Huang, R. (2019). Tea polyphenols: application in the control of oral. microorganism infectious diseases. Arch. Oral. Biol. 102, 74–82. doi: 10.1016/j.archoralbio.2019.03.027
Magro, L., Escadafal, C., Garneret, P., Jacquelin, B., Kwasiborski, A., Manuguerra, J. C., et al. (2017). Paper microfluidics for nucleic acid amplification testing (NAAT) of infectious diseases. Lab. Chip. 17, 2347–2371. doi: 10.1039/C7LC00013H
Man, O. M., Ramos, W. E., Vavala, G., Goldbeck, C., Ocasio, M. A., Fournier, J., et al. (2021). Optimizing Screening for Anorectal, Pharyngeal, and Urogenital Chlamydia. trachomatis and Neisseria. gonorrhoeae Infections in At-Risk Adolescents and Young Adults in New Orleans, Louisiana and Los Angeles, California, United States. Clin. Infect. Dis. 73, e3201–e3209. doi: 10.1093/cid/ciaa1838
Mansouri, S., Pajohi-Alamoti, M., Aghajani, N., Bazargani-Gilani, B., and Nourian, A. (2021). Stability and antibacterial activity of Thymus daenensis L. essential oil nanoemulsion in mayonnaise. J. Sci. Food. Agric. 101, 3880–3888. doi: 10.1002/jsfa.11026
Miller, C. J., Alexander, N. J., Gettie, A., Hendrickx, A. G., and Marx, P. A. (1992). The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. Fertil. Steril. 57, 1126–8. doi: 10.1016/S0015-0282(16)55038-9
Muñoz, K. J., Tan, M., and Sütterlin, C. (2022). Differential Effects of Small Molecule Inhibitors on the Intracellular Chlamydia Infection. mBio. 13, e0107622. doi: 10.1128/mbio.01076-22
Muñoz, K. J., Wang, K., Sheehan, L. M., Tan, M., and Sütterlin, C. (2021). The Small Molecule H89 Inhibits Chlamydia Inclusion Growth and Production of Infectious Progeny. Infect. Immun. 89, e0072920. doi: 10.1128/IAI.00729-20
Muschiol, S., Bailey, L., Gylfe, A., Sundin, C., Hultenby, K., Bergström, S., et al. (2006). A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia. trachomatis. Proc. Natl. Acad. Sci. U. S. A. 103, 14566–14571. doi: 10.1073/pnas.0606412103
Mwangi, J., Hao, X., Lai, R., and Zhang, Z. Y. (2019). Antimicrobial peptides: new hope in the war against multidrug resistance. Zool. Res. 40, 488–505. doi: 10.24272/j.issn.2095-8137.2019.062
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on Prevention and Control of Sexually Transmitted Infections in the United States. (2021). Sexually Transmitted Infections: Adopting a Sexual Health Paradigm, eds S. H. Vermund, A. B. Geller, and J. S. Crowley. National Academies Press. doi: 10.17226/25955
Núñez-Otero, C., Bahnan, W., Vielfort, K., Silver, J., Singh, P., Elbir, H., et al. (2021). A 2-pyridone amide inhibitor of transcriptional activity in Chlamydia. trachomatis. Antimicrob. Agents. Chemother. 65, e01826–20. doi: 10.1128/AAC.01826-20
O'Brien, K. S., Emerson, P., Hooper, P. J., Reingold, A. L., Dennis, E. G., Keenan, J. D., et al. (2019). Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet. Infect. Dis. 19, e14–e25. doi: 10.1016/S1473-3099(18)30444-4
Ohman, H., Tiitinen, A., Halttunen, M., Paavonen, J., and Surcel, H. M. (2011). Cytokine gene polymorphism and Chlamydia. trachomatis-specific immune responses. Hum. Immunol. 72, 278–82. doi: 10.1016/j.humimm.2010.12.012
Olsen, A. W., Follmann, F., Erneholm, K., Rosenkrands, I., and Andersen, P. (2015). Protection Against Chlamydia. trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. J. Infect. Dis. 212, 978–989. doi: 10.1093/infdis/jiv137
Osaka, I., and Hefty, P. S. (2014). Lipopolysaccharide-binding alkylpolyamine DS-96 inhibits Chlamydia. trachomatis infection by blocking attachment and entry. Antimicrob. Agents. Chemother. 58, 3245–3254. doi: 10.1128/AAC.02391-14
Paes, W., Brown, N., Brzozowski, A. M., Coler, R., Reed, S., Carter, D., et al. (2016). Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intravaginal Chlamydia. trachomatis infection in mice. Vaccine. 34, 4123–4131. doi: 10.1016/j.vaccine.2016.06.081
Pandolfi, F., Franza, L., Todi, L., Carusi, V., Centrone, M., Buonomo, A., et al. (2018). The Importance of Complying with Vaccination Protocols in Developed Countries: “Anti-Vax” Hysteria and the Spread of Severe Preventable Diseases. Curr. Med. Chem. 25, 6070–6081. doi: 10.2174/0929867325666180518072730
Panzetta, M. E., Valdivia, R. H., and Saka, H. A. (2018). Chlamydia Persistence: A Survival Strategy to Evade Antimicrobial Effects in-vitro and in-vivo. Front. Microbiol. 9, 3101. doi: 10.3389/fmicb.2018.03101
Park, S. K., Cho, S., Lee, I. H., Jeon, D. S., Hong, S. H., Smego, R. A., et al. (2007). Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary. tuberculosis. Int. J. Infect. Dis. 11, 434–440. doi: 10.1016/j.ijid.2006.12.004
Polaris Observatory Collaborators (2018). Global prevalence, treatment, and prevention of hepatitis. B. virus infection in 2016: a modelling study. Lancet. Gastroenterol. Hepatol. 3, 383–403. doi: 10.1016/S2468-1253(18)30056-6
Pollard, A. J., and Bijker, E. M. (2021). A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100. doi: 10.1038/s41577-020-00479-7
Porritt, R. A., and Crother, T. R. (2016). Chlamydia. pneumoniae Infection and Inflammatory Diseases. For. Immunopathol. Dis. Therap. 7, 237–254. doi: 10.1615/ForumImmunDisTher.2017020161
Premachandra, N. M., and Jayaweera, J. (2022). Chlamydia pneumoniae infections and development of lung cancer: systematic review. Infect. Agent. Cancer. 17, 11. doi: 10.1186/s13027-022-00425-3
Puysseleyr, D. e., De Puysseleyr, L., Rybarczyk, K., Vander Donck, J., De Vos, P. W. H., and Vanrompay, D. (2021). Transferrins Reduce Replication of Chlamydia. suis in McCoy Cells. Pathogens. 10, 858. doi: 10.3390/pathogens10070858
Reygaert, W. C. (2018). Green Tea Catechins: Their Use in Treating and Preventing Infectious Diseases. Biomed. Res. Int. 2018, 9105261. doi: 10.1155/2018/9105261
Richardson, B. A., Lavreys, L., Martin, H. L. Jr., Stevens, C. E., Ngugi, E., Mandaliya, K., et al. (2001). Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex. Transm. Dis. 28, 394–400. doi: 10.1097/00007435-200107000-00006
Roberts, M. C. (1996). Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS. Microbiol. Rev. 19, 1–24. doi: 10.1111/j.1574-6976.1996.tb00251.x
Roulis, E., Polkinghorne, A., and Timms, P. (2013). Chlamydia. pneumoniae: modern insights into an ancient pathogen. Trends. Microbiol. 21, 120–8. doi: 10.1016/j.tim.2012.10.009
Rowe-Magnus, D. A., Kao, A. Y., Prieto, A. C., Pu, M., and Kao, C. (2019). Cathelicidin Peptides Restrict Bacterial Growth via Membrane Perturbation and Induction of Reactive Oxygen Species. mBio. 10, e02021-19. doi: 10.1128/mBio.02021-19
Sajilata, M. G., Bajaj, P. R., and Singhal, R. S. (2008). Tea Polyphenols as Nutraceuticals. Compr. Rev. Food. Sci. Food. Saf. 7, 229–254. doi: 10.1111/j.1541-4337.2008.00043.x
Sanchez, L. R., Godoy, G. J., Gorosito Serran, M., Breser, M. L., Fiocca Vernengo, F., Engel, P., et al. (2019). IL-10 Producing B Cells Dampen Protective T Cell Response and Allow Chlamydia. muridarum Infection of the Male Genital Tract. Front. Immunol. 10, 356. doi: 10.3389/fimmu.2019.00356
Sandoz, K. M., and Rockey, D. D. (2010). Antibiotic resistance in Chlamydiae. Future. Microbiol. 5, 1427–1442. doi: 10.2217/fmb.10.96
Schachter, J., and Caldwell, H. D. (1980). Chlamydiae. Annu. Rev. Microbiol. 34, 285–309. doi: 10.1146/annurev.mi.34.100180.001441
Schmidt, S., Barbour, A., Sahre, M., Rand, K. H., and Derendorf, H. (2008). PK/PD: new insights for antibacterial and antiviral applications. Curr. Opin. Pharmacol. 8, 549–56. doi: 10.1016/j.coph.2008.06.010
Seleem, M. A., Wood, N. A., Brinkworth, A. J., Manam, S., Carabeo, R. A., Murthy, A. K., et al. (2022). In Vitro and In Vivo Activity of (Trifluoromethyl)pyridines as Anti-Chlamydia. trachomatis Agents. ACS. Infect. Dis. 8, 227–241. doi: 10.1021/acsinfecdis.1c00553
Sessa, R., Pietro, D. i., Filardo, M., Bressan, S., Rosa, A., Cutone, L., et al. (2017). Effect of bovine lactoferrin on Chlamydia. trachomatis. infection and inflammation. Biochem. Cell. Biol. 95, 34–40. doi: 10.1139/bcb-2016-0049
Sexually Transmitted Disease Surveillance (2020). National Overview. Available online at: https://www.Cdc.Gov/std/statistics/2020/overview.Htm#chlamydia (accessed on May 11, 2020).
Shaw, K. A., Szablewski, C. M., Kellner, S., Kornegay, L., Bair, P., Brennan, S., et al. (2019). Psittacosis Outbreak among Workers at Chicken Slaughter Plants, Virginia and Georgia, USA, 2018. Emerg. Infect. Dis. 25, 2143–2145. doi: 10.3201/eid2511.190703
Skinner, M. C., Kiselev, A. O., Isaacs, C. E., Mietzner, T. A., Montelaro, R. C., Lampe, M. F., et al. (2010). Evaluation of WLBU2 peptide and 3-O-octyl-sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia. trachomatis. Antimicrob. Agents. Chemother. 54, 627–636. doi: 10.1128/AAC.00635-09
Stary, G., Olive, A., Radovic-Moreno, A. F., Gondek, D., Alvarez, D., Basto, P. A., et al. (2015). VACCINES. A mucosal vaccine against Chlamydia. trachomatis generates two waves of protective memory T cells. Science. 348, aaa8205. doi: 10.1126/science.aaa8205
Tanphaichitr, N., Srakaew, N., Alonzi, R., Kiattiburut, W., Kongmanas, K., Zhi, R., et al. (2016). Potential Use of Antimicrobial Peptides as Vaginal Spermicides/Microbicides. Pharmaceuticals. (Basel). 9, 13. doi: 10.3390/ph9010013
Thomas, C., Moraga, I., Levin, D., Krutzik, P. O., Podoplelova, Y., Trejo, A., et al. (2011). Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 146, 621–632. doi: 10.1016/j.cell.2011.06.048
Törmäkangas, L., Vuorela, P., Saario, E., Leinonen, M., Saikku, P., Vuorela, H., et al. (2005). In vivo treatment of acute Chlamydia. pneumoniae infection with the flavonoids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse model. Biochem. Pharmacol. 70, 1222–30. doi: 10.1016/j.bcp.2005.07.012
Ur-Rehman, T., Slepenkin, A., Chu, H., Blomgren, A., Dahlgren, M. K., Zetterström, C. E., et al. (2012). Preclinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion. J. Antibiot. (Tokyo). 65, 397–404. doi: 10.1038/ja.2012.43
Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., et al. (2002). Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 360, 971–977. doi: 10.1016/S0140-6736(02)11079-8
Van Droogenbroeck, C., Beeckman, D. S., Harkinezhad, T., Cox, E., and Vanrompay, D. (2008). Evaluation of the prophylactic use of ovotransferrin against chlamydiosis in SPF turkeys. Vet. Microbiol. 132, 372–378. doi: 10.1016/j.vetmic.2008.05.028
Van Droogenbroeck, C., Dossche, L., Wauman, T., Van Lent, S., Phan, T. T., Beeckman, D. S., et al. (2011). Use of ovotransferrin as an antimicrobial in turkeys naturally infected with Chlamydia. psittaci, avian. metapneumovirus and Ornithobacterium. rhinotracheale. Vet. Microbiol. 153, 257–263. doi: 10.1016/j.vetmic.2011.05.016
Vashishtha, V. M., and Kamath, S. (2016). A Brief History of Vaccines Against Polio. Indian. Pediatr. 53, S20–S27.
Virok, D. P., Raffai, T., Kókai, D., Paróczai, D., Bogdanov, A., Veres, G., et al. (2019). Indoleamine 2, 3.-Dioxygenase Activity in Chlamydia. muridarum and Chlamydia. pneumoniae Infected Mouse Lung Tissues. Front. Cell. Infect. Microbiol. 9, 192. doi: 10.3389/fcimb.2019.00192
Vodstrcil, L. A., McIver, R., Huston, W. M., Tabrizi, S. N., Timms, P., Hocking, J. S., et al. (2015). The Epidemiology of Chlamydia. trachomatis Organism Load During Genital Infection: A Systematic Review. J. Infect. Dis. 211, 1628–45. doi: 10.1093/infdis/jiu670
Vuorelaa, P., Leinonenb, M., Saikkuc, P., Tammelaa, P., Rauhad, J. P., Wennberge, T., et al. (2004). Natural products in the process of finding new drug candidates. Curr. Med. Chem. 11, 1375–1389. doi: 10.2174/0929867043365116
Wang, B., Timilsena, Y. P., Blanch, E., and Adhikari, B. (2019). Lactoferrin: Structure, function, denaturation and digestion. Crit. Rev. Food. Sci. Nutr. 59, 580–596. doi: 10.1080/10408398.2017.1381583
Weber, J., Nunn, A., O'Connor, T., Jeffries, D., Kitchen, V., McCormack, S., et al. (2001). 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89, 6PD.) in vitro and in vivo. Aids. 15, 1563–1568. doi: 10.1097/00002030-200108170-00014
Wilkinson, D., Tholandi, M., Ramjee, G., and Rutherford, G. W. (2002). Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet. Infect. Dis. 2, 613–7. doi: 10.1016/S1473-3099(02)00396-1
Wolf, K., Betts, H. J., Chellas-Géry, B., Hower, S., Linton, C. N., Fields, K. A., et al. (2006). Treatment of Chlamydia. trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol. Microbiol. 61, 1543–55. doi: 10.1111/j.1365-2958.2006.05347.x
Xiang, W., Yu, N., Lei, A., Li, X., Tan, S., Huang, L., et al. (2021). Insights Into Host Cell Cytokines in Chlamydia Infection. Front. Immunol. 12, 639834. doi: 10.3389/fimmu.2021.639834
Yamazaki, T., Inoue, M., Sasaki, N., Hagiwara, T., Kishimoto, T., Shiga, S., et al. (2003). In vitro inhibitory effects of tea polyphenols on the proliferation of Chlamydia. trachomatis and Chlamydia. pneumoniae. Jpn. J. Infect. Dis. 56, 143–5.
Yamazaki, T., Kishimoto, T., Shiga, S., Sato, K., Hagiwara, T., Inoue, M., et al. (2005). Biosynthesized tea polyphenols inactivate Chlamydia. trachomatis in vitro. Antimicrob. Agents. Chemother. 49, 2501–3. doi: 10.1128/AAC.49.6.2501-2503.2005
Yang, C. C., Wu, C. J., Chien, C. Y., and Chien, C. T. (2021). Green Tea Polyphenol Catechins Inhibit Coronavirus Replication and Potentiate the Adaptive Immunity and Autophagy-Dependent Protective Mechanism to Improve Acute Lung Injury in Mice. Antioxidants. (Basel). 10, 928. doi: 10.3390/antiox10060928
Yasin, B., Pang, M., and Wagar, E. A. (2004). A cumulative experience examining the effect of natural and synthetic antimicrobial peptides vs. Chlamydia. trachomatis. J. Pept. Res. 64, 65–71. doi: 10.1111/j.1399-3011.2004.00172.x
Yoon, B. K., Jackman, J. A., Kim, M. C., and Cho, N. J. (2015). Spectrum of Membrane Morphological Responses to Antibacterial Fatty Acids and Related Surfactants. Langmuir. 31, 10223–32. doi: 10.1021/acs.langmuir.5b02088
Yoon, B. K., Jackman, J. A., Valle-González, E. R., and Cho, N. J. (2018). Antibacterial Free Fatty Acids and Monoglycerides: Biological Activities, Experimental Testing, and Therapeutic Applications. Int. J. Mol. Sci. 19, 1114. doi: 10.3390/ijms19041114
Zheng, X., Wu, Y., Bi, J., Huang, Y., Cheng, Y., Li, Y., et al. (2022). The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell. Mol. Immunol. 19, 192–209. doi: 10.1038/s41423-021-00786-6
Zhong, G. (2017). Chlamydial plasmid-dependent pathogenicity. Trends Microbiol. 25, 141–152. doi: 10.1016/j.tim.2016.09.006
Keywords: Chlamydia, chlamydial infection, antibiotic therapy, anti-chlamydial compounds, non-antibiotic approaches
Citation: Hou C, Jin Y, Wu H, Li P, Liu L, Zheng K and Wang C (2022) Alternative strategies for Chlamydia treatment: Promising non-antibiotic approaches. Front. Microbiol. 13:987662. doi: 10.3389/fmicb.2022.987662
Received: 06 July 2022; Accepted: 04 November 2022;
Published: 23 November 2022.
Edited by:
Ying Zhang, Zhejiang University, ChinaReviewed by:
I-Hsiu Huang, Oklahoma State University Center for Health Sciences, United StatesFabian Kong, The University of Melbourne, Australia
Copyright © 2022 Hou, Jin, Wu, Li, Liu, Zheng and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kang Zheng, emhlbmdrYW5nMTIyMSYjeDAwMDQwO3NpbmEuY29t; Chuan Wang, d2FuZ2NodWFuJiN4MDAwNDA7dXNjLmVkdS5jbg==
†These authors have contributed equally to this work